Loading
A phase 1/2 trial of IN10018 and Furmonertinib in non-small-cell lung cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC is a phase 1/2 interventional study registered as NCT05994131 by InxMed (Shanghai) Co., Ltd., with 110 participants planned, started 2023-07-13 and due to reach its primary completion in 2026-07-31. Interventions recorded: IN10018 and Furmonertinib.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Furmonertinib, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.